21409-25-6

Usage

Uses

Used in Pharmaceutical Industry:
Diphenylmethoxyacetic acid is used as a metabolite of diphenhydramine for the treatment of numerous allergic ailments such as allergic rhinitis, asthma, anaphylaxis, and others. Its presence in the body is a result of the metabolism of diphenhydramine, which aids in managing these allergic conditions.

InChI:InChI=1/C15H14O3/c16-14(17)11-18-15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H,16,17)

Upstream product

• 1204-50-8 benzhydrol sodium salt 
• 79-08-3 bromoacetic acid 
• 91-01-0 1,1-Diphenylmethanol 
• 105-36-2 ethyl bromoacetate 
• 118286-11-6 ethyl 2-(benzhydryloxy)acetate 
• 79-14-1 glycolic Acid 
• 79-11-8 chloroacetic acid 

Downstream Products

• 2029-82-5 1-(Diphenylmethoxy)-2-methylpropan-2-ol 
• 736933-40-7 (2S)-2-benzhydryloxy-1-(2,5-dimethoxy-phenyl)-hept-4-en-1-one 

Relevant academic research and scientific papers

HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (I) where Z is N or CHNR2 and X is NR2, O, S, S=O or SO2. Among other definitions for R, R1, W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR3Ar2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR3 and (Ar1)2CR4 is optionally substituted benzhydryl.

Total synthesis of the hydroxyketone kurasoin A using asymmetric phase-transfer alkylation

The total synthesis of the farnesyltransferase inhibitor kurasoin A has been achieved using a novel asymmetric phase-transfer-catalyzed glycolate alkylation reaction. 2,5-Dimethoxyacetophenone 7 with cinchonidinium catalyst 9 (10 mol %) and hydroxide base

Asymmetric phase-transfer catalyzed glycolate alkylation, investigation of the scope, and application to the synthesis of (-)-ragaglitazar

Asymmetric glycolate alkylation using a protected acetophenone surrogate under solid-liquid phase-transfer conditions is a new approach to the synthesis of 2-hydroxy esters and acids. Diphenylmethyloxy-2,5-dimethoxyacetophenone 1 with a trifluorobenzyl ci

Phase-transfer-catalyzed asymmetric glycolate alkylation

Asymmetric surrogate glycolate alkylation has been performed under phase-transfer conditions. Diphenylmethyloxy-2,5-dimethoxyacetophenone with trifluorobenzyl cinchonidinium catalyst and cesium hydroxide provided alkylation products at -35°C in high yield

BENZOXAZINONE DERIVATIVE

A benzoxazinone derivative represented by general formula (I) or a pharmaceutically acceptable acid addition salt thereof, and an anti-inflammatory, a neutrophil infiltration inhibitor and a serine protease inhibitor each containing the derivative as an active ingredient, wherein R, R1, R2 and R3 may be the same or different from one another and each represents hydrogen or lower alkyl; A represents optionally halogenated phenyl, heterocycle or adamantyl; B represents hydrogen or optionally halogenated phenyl or heterocycle; U represents =CH-, =C= or =N-; V represents -O-, -CH2-, =N-, -NH-, -CH= or a single bond; X represents -O-, =CH-, -CH2- or a single bond; Y represents -CH2-, -NH-, -O- or a single bond; Z represents -CO- or -CH2-; and l represents an integer of 0 to 3. This compound has excellent activities of inhibiting serine protease, neutrotaxis, and infiltration of neutrophils into carragheenin-induced pneumocephalus.ψ

Synthesis and Structure-Activity Relationships of 1-Acyl-4-(2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists

A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines, with increased oral activity was prepared and evaluated in vitro in PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP).Oral activity was ascertained through a PAF-induced mortality test in mice (MOR).Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test.Three different types of acylsubstituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups.The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 μM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR-12519, PAG IC50 = 0.041 μM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086.Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests.On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.